Heparin induced thrombocytopenia type II after the use of low-molecular-weight heparin. Case report and rewiew of the literature

被引:0
作者
Franke, J [1 ]
Schaeper, O [1 ]
Kayser, R [1 ]
Mahlfeld, K [1 ]
机构
[1] Otto Von Guericke Univ, Orthopad Klin, D-39120 Magdeburg, Germany
来源
UNFALLCHIRURG | 2003年 / 106卷 / 01期
关键词
low molecular weight heparin; Hheparin induced thrombocytopenia; HIT-Type-II; hirudin;
D O I
10.1007/s00113-002-0503-7
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction. It has been suggested,that HIT-type-II can occur both after the use of low-molecular-weight and unfractionated heparin. The present study investigates the incidence of HIT-type-II after the use of low molecular weight heparin by reviewing the literature and describes one own case. Case report. We observed in a 72 year old female patient a HIT-type-II, who received low molecular weight heparin (Clexane 40 o.a.d) after the implantation of an endo-prothesis as thrombosis prophylaxis. This occurred on the 9(th) postoperative day. One year later we performed a second endoprosthesis operation of the contralateral site without complications. With the known HIT-type-II, diagnosed the year before, we used hirudin (Refludan) for thrombosis prophylaxis. Result. A critical view on the international literature revealed only a few cases, where a HIT-type-II was caused by the use of low molecular weight heparin. The incidence seems to be much lower than correlated to the use of unfractionated heparin. Conclusion. It is possible to suffer from a HIT-type-II after low molecular weight heparin. This study confirms the suspicion that the incidence of a HIT-type-II after low molecular weight is lower than after unfractionated heparin. Therefore the further use of unfractioned heparin for thrombosis prophylaxis has to be questioned and low molecular-weight heparin should be preferred.
引用
收藏
页码:77 / 81
页数:5
相关论文
共 27 条
  • [1] BALESTRA B, 1994, EUR J HAEMATOL, V53, P61
  • [2] BALL A, 1989, PRESSE MED, V18, P1254
  • [3] BEDOCK B, 1990, PRESSE MED, V19, P720
  • [4] BREDDIN HK, 1995, HEPARIN, V1, P2
  • [5] THROMBOCYTOPENIA AFTER A LOW-MOLECULAR-WEIGHT HEPARIN
    CHIN, SP
    ALVADO, G
    LEMOINE, P
    [J]. ANNALES FRANCAISES D ANESTHESIE ET DE REANIMATION, 1992, 11 (05): : 587 - 591
  • [6] CHONG BH, 1989, BLOOD, V73, P1592
  • [7] THROMBOCYTOPENIA ASSOCIATED WITH LOW-MOLECULAR-WEIGHT HEPARIN
    EICHINGER, S
    KYRLE, PA
    BRENNER, B
    WAGNER, B
    KAPIOTIS, S
    LECHNER, K
    KORNINGER, HC
    [J]. LANCET, 1991, 337 (8754) : 1425 - 1426
  • [8] Dangerous potentials in medicamentous prophylaxis of thrombosis - Low molecular-weight heparins versus standard heparins.
    Ganzer, D
    Gutezeit, A
    Mayer, G
    [J]. ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 1999, 137 (05): : 457 - 461
  • [9] Thromboembolism prophylaxis as a cause of thromboembolic complications. An investigation into the incidence of heparin-induced thrombocytopenia (HIT) type II
    Ganzer, D
    Gutezeit, A
    Mayer, G
    Greinacher, A
    Eichler, P
    [J]. ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE, 1997, 135 (06): : 543 - 549
  • [10] Recombinant hirudin (Lepirndin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia -: A prospective study
    Greinacher, A
    Völpel, H
    Janssens, U
    Hach-Wunderle, V
    Kemkes-Matthes, B
    Eichler, P
    Mueller-Velten, HG
    Pötzsch, B
    [J]. CIRCULATION, 1999, 99 (01) : 73 - 80